SEC Comment Letter for CYTOKINETICS INC (CYTK) (CIK 0001061983) (CYTK) — Dec 28, 2016
CYTOKINETICS INC (CYTK) (CIK 0001061983)
Date: Dec. 28, 2016 · CIK: 0001061983 · Accession: 0000000000-16-106668
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 4546 December 22, 2016 Robert I. Blum President & Chief Executive Officer Cytokinetics, Incorporated 280 East Grand Avenue South San Francisco, C A 94080
Re: Cytokinetics, Incorporated Registration Statement on Form S -3 Filed December 16, 2016 File No. 333 -215147
Dear Mr. Blum :
We have limited our review of your registration statement to the resolution of your pending request for confidential treatment. Please be advised that we will not be in a position to declare your registration statement effective until we resolve all issues concerning the confidential treatment request .
We remind you that the company and its management are responsible for the accur acy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please r efer to Rules 460 and 461 regarding requests for acceleration .
Please contact Dorrie Yale at 202 -551-8776 or Erin Jaskot, Spe cial Counsel, at 202 -551- 3442 with any other questions.
Sincerely,
/s/ Erin K. Jaskot, for
Show Raw Text
Mail Stop 4546 December 22, 2016 Robert I. Blum President & Chief Executive Officer Cytokinetics, Incorporated 280 East Grand Avenue South San Francisco, C A 94080 Re: Cytokinetics, Incorporated Registration Statement on Form S -3 Filed December 16, 2016 File No. 333 -215147 Dear Mr. Blum : We have limited our review of your registration statement to the resolution of your pending request for confidential treatment. Please be advised that we will not be in a position to declare your registration statement effective until we resolve all issues concerning the confidential treatment request . We remind you that the company and its management are responsible for the accur acy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please r efer to Rules 460 and 461 regarding requests for acceleration . Please contact Dorrie Yale at 202 -551-8776 or Erin Jaskot, Spe cial Counsel, at 202 -551- 3442 with any other questions. Sincerely, /s/ Erin K. Jaskot, for Suzanne Hayes Assistant Director Office of Insurance and Healthcare cc: Michael E. Tenta Cooley LLP